ravive, Inc. (NASDAQ:ARAV, ", the Company", ))))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place February 16-18, 2023 in San Francisco and virtually. The poster presentation will highlight updated results from the Phase 1b portion of the trial in 26 patients with advanced or metastatic ccRCC who have progressed after 1 or 2 prior lines of immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies.
S&P 500 Gains 0.5%; US Foods Shares Rise After Q4 Results
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 250 points on Thursday.
The Dow traded up 0.75% to 38,713.88 while the NASDAQ rose 0.22% to 15,894.39. The S&P 500 also rose, gaining, 0.52% to 5,026.65.
